AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company's proprietary LENSai™ platform, an AI-driven system that analyzes evolutionary patterns in biological data, these novel AI-generated sequences have been optimized to maximize therapeutic performance while improving the patient experience...
Advancing GLP-1 Therapies
Current GLP-1 drugs for diabetes and obesity management often require frequent injections due to their short half-life. In just two weeks, IPA's LENSai generated, developed and optimized novel genetic sequences for GLP-1-like constructs that may offer potential advantages over existing treatments...
From AI Discovery to Preclinical Optimization
IPA’s LENSai™ platform identified key molecular features by analyzing evolutionary patterns across species...
Exploring a Novel Drug Delivery Approach
Given the unique and miniature nature of the therapeutic molecules as well as their selected gene therapy delivery vehicle, IPA is further evaluating the feasibility of delivering these GLP-1-like therapies via a transdermal patch rather than injection...
A Paradigm Shift in Biologic Innovation
IPA's proprietary HYFT patterns, the core of our LENSai software, are driving a revolution in therapeutic drug discovery...
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence...
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws...